Immutep Ltd Suspended from Quotation
Key points
- Immutep requests voluntary suspension of trading pending announcement of TACTI-004 Phase III trial futility analysis outcome
- Suspension to remain in place until earlier of announcement release or trading on 13 March 2026
- Suspension requested to ensure trading does not occur in uninformed market
Full summary
Immutep Ltd (ASX: IMM) has requested a voluntary suspension of trading in its ordinary shares effective immediately. The suspension is requested pending the announcement of the outcome of the pre-specified interim futility analysis for the TACTI-004 (KEYNOTE-F91) Phase III trial evaluating its lead candidate, eftilagimod alfa. Immutep has requested the suspension to ensure that trading does not take place in an uninformed market. The suspension is expected to remain in place until the earlier of Immutep making an announcement regarding the futility analysis or the commencement of trading on Friday, 13 March 2026. Immutep anticipates that the voluntary suspension will cease upon it announcing the outcome of the futility analysis.
Summary generated by a large language model. Please interpret with care.